Microencapsulated Chitosan-Based Nanocapsules: A New Platform for Pulmonary Gene Delivery.

chitosan nanocapsules in vivo study microspheres pCMV-βGal pulmonary gene delivery spray-drying

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
31 Aug 2021
Historique:
received: 25 04 2021
revised: 27 05 2021
accepted: 31 05 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

In this work, we propose chitosan (CS)-based nanocapsules (NCs) for pulmonary gene delivery. Hyaluronic acid (HA) was incorporated in the NCs composition (HA/CS NCs) aiming to promote gene transfection in the lung epithelium. NCs were loaded with a model plasmid (pCMV-βGal) to easily evaluate their transfection capacity. The plasmid encapsulation efficiencies were of approx. 90%. To facilitate their administration to the lungs, the plasmid-loaded NCs were microencapsulated in mannitol (Ma) microspheres (MS) using a simple spray-drying technique, obtaining dry powders of adequate properties. In vivo, the MS reached the deep lung, where the plasmid-loaded CS-based NCs were released and transfected the alveolar cells more homogeneously than the control formulation of plasmid directly microencapsulated in Ma MS. The HA-containing formulation achieved the highest transfection efficiency, in a more extended area and more homogeneously distributed than the rest of tested formulations. The new micro-nanostructured platform proposed in this work represents an efficient strategy for the delivery of genetic material to the lung, with great potential for the treatment of genetic lung diseases.

Identifiants

pubmed: 34575452
pii: pharmaceutics13091377
doi: 10.3390/pharmaceutics13091377
pmc: PMC8472419
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : FEDER/Ministry of Science and Innovation-State Research Agency of Spain, within the frame-work of the State Program of Generation of Knowledge and Scientific and Technological Strengthening of the System of I+D+i and of the State Program of I+D+i Oriented
ID : Project PID2019-107500RB-I00
Organisme : Instituto de Salud Carlos III of Spain (Strategic Health Action)
ID : Project FIS PSI14/00059
Organisme : Xunta de Galicia (Consellería de Cultura, Educación e Ordenación Universitaria, Project Compet-itive Reference Groups)
ID : ED431C 2017/09-FEDER

Références

Sci Rep. 2019 Aug 9;9(1):11565
pubmed: 31399627
Int J Pharm. 2016 Jan 30;497(1-2):199-209
pubmed: 26656946
Invest Ophthalmol Vis Sci. 2008 May;49(5):2016-24
pubmed: 18436835
Mol Pharm. 2019 Feb 4;16(2):489-497
pubmed: 30092131
ACS Appl Mater Interfaces. 2020 Jun 10;12(23):25676-25682
pubmed: 32364369
J Control Release. 2012 Feb 10;157(3):383-90
pubmed: 21864592
J Control Release. 2006 May 30;112(3):382-8
pubmed: 16647780
Curr Gene Ther. 2019;19(2):93-99
pubmed: 31267871
J Biomater Sci Polym Ed. 2008;19(3):387-97
pubmed: 18325238
J Control Release. 2004 Jan 8;94(1):15-24
pubmed: 14684268
Histochem J. 1999 Apr;31(4):231-6
pubmed: 10447064
Int J Pharm. 2010 Jun 15;392(1-2):1-19
pubmed: 20223286
Sci Rep. 2015 May 13;5:10048
pubmed: 25970096
Int J Biochem Cell Biol. 2014 Jul;52:124-9
pubmed: 24560894
Macromol Biosci. 2008 May 13;8(5):441-50
pubmed: 18236434
Biomedicines. 2020 Sep 20;8(9):
pubmed: 32962254
Biomaterials. 2007 Feb;28(6):1280-8
pubmed: 17126901
Adv Drug Deliv Rev. 2018 Aug;133:5-18
pubmed: 29653129
Pharm Nanotechnol. 2017;5(4):243-249
pubmed: 28786352
Molecules. 2016 May 28;21(6):
pubmed: 27240337
Mol Pharm. 2014 Apr 7;11(4):1201-7
pubmed: 24533458
Molecules. 2019 Jul 15;24(14):
pubmed: 31311176
Int J Pharm. 2002 Dec 5;249(1-2):7-21
pubmed: 12433430
Pharm Res. 2002 Feb;19(2):169-74
pubmed: 11883644
Int J Pharm. 2010 Oct 31;399(1-2):1-11
pubmed: 20732398
Histochem Cell Biol. 2005 Jul;124(1):77-85
pubmed: 15947941
J Control Release. 2005 Jan 3;101(1-3):151-62
pubmed: 15588901
Nanotechnology. 2008 Feb 20;19(7):075105
pubmed: 21817630
Curr Pharm Des. 2018;24(23):2678-2691
pubmed: 30084325
Molecules. 2019 Apr 01;24(7):
pubmed: 30939857
Pharm Dev Technol. 2014 May;19(3):257-62
pubmed: 23528124
J Histochem Cytochem. 1999 Oct;47(10):1331-42
pubmed: 10490462
J Control Release. 2001 Feb 23;70(3):329-39
pubmed: 11182203
Cell Mol Life Sci. 2008 Feb;65(3):395-413
pubmed: 17965830
Clin Exp Pharmacol Physiol. 2003 Mar;30(3):203-5
pubmed: 12603352
Int J Pharm. 2016 Jul 25;509(1-2):107-117
pubmed: 27210735
Langmuir. 2008 Dec 2;24(23):13614-20
pubmed: 18959432
Acta Naturae. 2013 Apr;5(2):62-9
pubmed: 23819037
Int J Mol Sci. 2014 Apr 08;15(4):5852-73
pubmed: 24717409
Int J Pharm. 2009 Dec 1;382(1-2):205-14
pubmed: 19660537
Trends Biotechnol. 2007 Dec;25(12):563-70
pubmed: 17997181
Int J Pharm. 2010 May 5;390(1):84-8
pubmed: 19825403
Bioeng Transl Med. 2018 Oct 26;4(1):38-50
pubmed: 30680317
Drug Dev Ind Pharm. 2017 Jul;43(7):1071-1081
pubmed: 28270008
Int J Immunopathol Pharmacol. 2013 Jul-Sep;26(3):597-600
pubmed: 24067456
Front Immunol. 2018 Apr 19;9:791
pubmed: 29725329
Eur J Pharm Biopharm. 2004 Jan;57(1):1-8
pubmed: 14729076
Int J Pharm. 2018 Nov 15;551(1-2):23-33
pubmed: 30153489
Int J Pharm. 2015 Apr 10;483(1-2):212-9
pubmed: 25681727
Biomaterials. 2008 Aug-Sep;29(24-25):3477-96
pubmed: 18499247
Ther Deliv. 2017 Jul;8(8):647-661
pubmed: 28730933
Annu Rev Cell Dev Biol. 2007;23:435-61
pubmed: 17506690
Eur J Pharm Biopharm. 2008 May;69(1):83-93
pubmed: 18166446
Eur J Pharm Biopharm. 2015 Jan;89:163-74
pubmed: 25497488
J Clin Diagn Res. 2015 Jan;9(1):GE01-6
pubmed: 25738007
J Control Release. 2006 Apr 10;111(3):299-308
pubmed: 16481062
Eur J Pharm Sci. 2005 Jul-Aug;25(4-5):427-37
pubmed: 15893461
Pharm Res. 2006 Mar;23(3):549-56
pubmed: 16525861
J Aerosol Med Pulm Drug Deliv. 2014 Apr;27(2):81-93
pubmed: 24502451
Colloids Surf B Biointerfaces. 2013 Mar 1;103:615-23
pubmed: 23274155
J Cyst Fibros. 2011 Jan;10(1):1-8
pubmed: 20888307
Int J Pharm. 2020 Feb 15;575:118919
pubmed: 31816351
Int J Biol Macromol. 2020 May 15;151:1012-1029
pubmed: 31715233
Mol Pharm. 2017 Sep 5;14(9):2977-2990
pubmed: 28809501
Drug Des Devel Ther. 2013 Aug 28;7:861-73
pubmed: 24039397
Biomacromolecules. 2007 Jul;8(7):2072-9
pubmed: 17585804
PLoS One. 2013 Nov 18;8(11):e79954
pubmed: 24260326
J Control Release. 2019 Dec 28;316:393-403
pubmed: 31715279

Auteurs

Estefanía Fernández-Paz (E)

Nanobiofar Group, Department of Pharmacology, Pharmacy & Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.

Lucía Feijoo-Siota (L)

Department of Microbiology & Parasitology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.

Maria Manuela Gaspar (MM)

Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisboa, Av. Professor GamaPinto, 1649-003 Lisbon, Portugal.

Noemi Csaba (N)

Nanobiofar Group, Center of Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Campus Vida, 15706 Santiago de Compostela, Spain.

Carmen Remuñán-López (C)

Nanobiofar Group, Department of Pharmacology, Pharmacy & Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.

Classifications MeSH